- Morgan Stanley 15th Annual Global Healthcare Conference on 13 September -
- Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on 27 September -
LONDON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that GW executive management will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference on Wednesday, 13 September 2017 at 11:05 a.m. EDT at the Grand Hyatt Hotel in New York City and the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on Wednesday, 27 September 2017 at 2:30 p.m. EDT at the Lotte New York Palace in New York City.
A live audio webcast of the presentations will be available through GW’s corporate website at www.gwpharm.com on the Investors section under Events & Presentations. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), for which GW has commenced a rolling NDA submission with the FDA for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. The Company continues to evaluate Epidiolex in additional epilepsy conditions and currently has ongoing Phase 3 clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
CONTACT: Enquiries: GW Pharmaceuticals plc Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570